FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
FDA General

FDA Limited in Fighting Misinformation: Califf

Communications experts tell the Associated Press FDA may have a hard time combating misinformation due to several factors, including its reputation an...

latest-news-card-1
Federal Register

Info Collection on BLA Requirements

Federal Register notice: FDA sends to OMB an information collection extension entitled Biologics License Applications (BLAs) Procedures and Requiremen...

latest-news-card-1
Federal Register

510(k) Certification Information Collection

Federal Register notice: FDA revises an information collection entitled Premarket Notification 21 CFR Part 807, Subpart E.

latest-news-card-1
Medical Devices

510(k) Guidances for 2 Ultrasound-type Devices Published

FDA publishes two 510(k) guidances on ultrasound and related types of devices.

latest-news-card-1
Human Drugs

Intarcia Agrees to Advisory Committee to Resolve Review Dispute

Intarcia Therapeutics accepts an FDA proposal to allow an advisory committee to review and address a 2021 CDER decision not to approve the companys Ty...

latest-news-card-1
Federal Register

Lagevrio Misses Endpoint in Covid-19 Study

Merck says a study of its Covid-19 drug Lagevrio (molnupiravir) did not meet the primary endpoint a statistically significant risk reduction in those...

latest-news-card-1
Human Drugs

Regulatory Agenda Eyes DTC Ads and Med Guides

HHS publishes its semiannual regulatory agenda that outlines numerous FDA rulemaking activities under development, including a final rule on DTC Rx dr...

latest-news-card-1
Biologics

Pfizer Drops Many U.S. Lyme Trial Participants

Pfizer drops about half of the U.S. participants in its VALOR Lyme vaccine Phase 3 trial due to trial site good clinical practice violations.

latest-news-card-1
Human Drugs

Priority Review for Merck Prevymis sNDA

FDA grants priority review for a Merck sNDA to extend the use of its Prevymis to CMV prophylaxis in kidney transplant patients.

latest-news-card-1
Human Drugs

FDA to Review Iveric NDA for Avacincaptad Pegol

FDA accepts an Iveric Bio NDA for avacincaptad pegol for priority review with a Breakthrough Therapy designation to treat geographic atrophy secondary...